X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
melanoma (29) 29
index medicus (25) 25
oncology (24) 24
humans (20) 20
immunotherapy (19) 19
cancer (16) 16
metastatic melanoma (13) 13
survival (11) 11
article (10) 10
female (9) 9
metastasis (9) 9
targeted therapy (9) 9
vemurafenib (9) 9
male (8) 8
medicine, research & experimental (8) 8
middle aged (8) 8
mutations (8) 8
therapy (8) 8
braf (7) 7
cutaneous melanoma (7) 7
dermatology (7) 7
immunology (7) 7
melanoma - drug therapy (7) 7
metastases (7) 7
adult (6) 6
cell biology (6) 6
chemotherapy (6) 6
clinical trials (6) 6
inhibition (6) 6
ipilimumab (6) 6
melanoma - pathology (6) 6
mutation (6) 6
breast-cancer (5) 5
cancer therapies (5) 5
care and treatment (5) 5
drug resistance, neoplasm (5) 5
immune checkpoint (5) 5
immune checkpoint blockade (5) 5
melanoma - genetics (5) 5
melanoma - immunology (5) 5
open-label (5) 5
patients (5) 5
risk factors (5) 5
toxicity (5) 5
aged (4) 4
antineoplastic agents - therapeutic use (4) 4
biochemistry & molecular biology (4) 4
biomarkers (4) 4
ctla-4 blockade (4) 4
dabrafenib (4) 4
diagnosis (4) 4
disease-free survival (4) 4
double-blind (4) 4
lymphocytes (4) 4
neoplasm staging (4) 4
pharmacology & pharmacy (4) 4
proto-oncogene proteins b-raf - antagonists & inhibitors (4) 4
proto-oncogene proteins b-raf - genetics (4) 4
review (4) 4
risk groups (4) 4
trametinib (4) 4
tumor-infiltrating lymphocytes (4) 4
tumors (4) 4
uveal melanoma (4) 4
acquired-resistance (3) 3
adjuvant dabrafenib (3) 3
adolescent (3) 3
adolescents (3) 3
aged, 80 and over (3) 3
assay (3) 3
biopsy (3) 3
brain metastases (3) 3
cells (3) 3
children (3) 3
expression (3) 3
gene expression (3) 3
gene expression profiling (3) 3
genes (3) 3
medical prognosis (3) 3
medicine & public health (3) 3
methods (3) 3
nivolumab (3) 3
pathology (3) 3
pd-1 (3) 3
pd-1 protein (3) 3
phase-ii (3) 3
programmed cell death 1 receptor - antagonists & inhibitors (3) 3
protein kinase inhibitors - therapeutic use (3) 3
resistance (3) 3
response rates (3) 3
skin cancer (3) 3
skin neoplasms - drug therapy (3) 3
stage-iii (3) 3
stage-iii melanoma (3) 3
t cells (3) 3
usage (3) 3
analysis (2) 2
animals (2) 2
anti-pd-1 (2) 2
antigens (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 97 - 103
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 11/2018, Volume 70, pp. 144 - 153
Stage III melanoma encompasses a range of disease burdens, including microscopic foci of metastatic melanoma in a sentinel lymph node; bulky, clinically... 
Neoadjuvant | Adjuvant | Targeted therapy | Immunotherapy | Melanoma | STAGE-III MELANOMA | OPEN-LABEL | RADIATION-THERAPY | METASTATIC MELANOMA | DABRAFENIB PLUS TRAMETINIB | ONCOLOGY | HIGH-DOSE INTERFERON-ALPHA-2B | CUTANEOUS MELANOMA | DOUBLE-BLIND | PEGYLATED INTERFERON-ALPHA-2B | COOPERATIVE-ONCOLOGY-GROUP | Metastasis
Journal Article
Cancer Discovery, ISSN 2159-8274, 08/2016, Volume 6, Issue 8, pp. 827 - 837
Journal Article
American Journal of Clinical Dermatology, ISSN 1175-0561, 10/2018, Volume 19, Issue 5, pp. 639 - 646
Journal Article
Science Translational Medicine, ISSN 1946-6234, 03/2017, Volume 9, Issue 379, p. eaah3560
Journal Article
Nature Medicine, ISSN 1078-8956, 11/2018, Volume 24, Issue 11, pp. 1649 - 1654
Journal Article
Therapeutic Advances in Medical Oncology, ISSN 1758-8340, 02/2019, Volume 11, p. 1758835919830826
The development of BRAF and MEK inhibitors (BRAFis and MEKis) and immune checkpoint inhibitors have changed the management of advanced stage melanoma and... 
targeted therapy | BRAF inhibitor | melanoma | MEK inhibitor | tumor microenvironment | immunotherapy | T-CELL RECOGNITION | PD-L1 EXPRESSION | COMBINED NIVOLUMAB | OPEN-LABEL | ANTITUMOR-ACTIVITY | COMBINATION | INHIBITION | ONCOLOGY | DOUBLE-BLIND | BRAF-MUTANT MELANOMA | VEMURAFENIB
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 11/2013, Volume 62, Issue 11, pp. 1711 - 1722
Journal Article
Journal Article